Cargando…
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
BACKGROUND: Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients managed with active surveillance (AS) is not well described in the literature. METHODS: This was a prospective observational s...
Autores principales: | Harrison, Michael R., Costello, Brian A., Bhavsar, Nrupen A., Vaishampayan, Ulka, Pal, Sumanta K., Zakharia, Yousef, Jim, Heather S. L., Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che‐Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Inman, Brant A., Mardekian, Jack, Borham, Azah, George, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251950/ https://www.ncbi.nlm.nih.gov/pubmed/33765337 http://dx.doi.org/10.1002/cncr.33494 |
Ejemplares similares
-
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
por: Costello, Brian A., et al.
Publicado: (2022) -
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019) -
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
por: Jeyakumar, Ghayathri, et al.
Publicado: (2017) -
The Year in Review for Renal Cancer
por: Vaishampayan, Ulka
Publicado: (2020) -
The power of meta-analysis in therapeutic decision making for advanced kidney cancer
por: Vaishampayan, Ulka
Publicado: (2019)